Sixth Element Capital

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, focused on developing innovative treatments for hormone-resistant breast and prostate cancer patients. Founded in 2017, the company is dedicated to creating a pipeline of small molecules that selectively inhibit pioneer factors, addressing significant unmet clinical needs in cancer treatment. By targeting these specific mechanisms, Azeria aims to enhance the effectiveness of therapies for patients facing these challenging cancer types.

Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, focused on developing innovative treatments for hormone-resistant breast and prostate cancer patients. Founded in 2017, the company is dedicated to creating a pipeline of small molecules that selectively inhibit pioneer factors, addressing significant unmet clinical needs in cancer treatment. By targeting these specific mechanisms, Azeria aims to enhance the effectiveness of therapies for patients facing these challenging cancer types.

AdoRx Therapeutics Limited is a UK-based drug discovery company founded in 2017, focused on developing new cancer therapeutics by modulating the adenosine pathway. High levels of adenosine in the tumor microenvironment allow cancer cells to evade immune detection, presenting a significant challenge in treatment. AdoRx is dedicated to designing effective adenosine receptor antagonists aimed at counteracting these effects and enhancing the immune response against tumors. The company boasts a leadership team with extensive experience in biotechnology and pharmaceuticals, having discovered over 25 clinical candidates collectively. By concentrating on the adenosine pathway, AdoRx Therapeutics aims to create innovative solutions that improve cancer treatment outcomes.

NeoPhore Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on the discovery and development of novel small molecule therapies for cancer treatment. Established in 2017, the company specializes in immuno-oncology therapeutics that aim to stimulate the immune system. NeoPhore's innovative therapies target genetic mechanisms to create neoantigens, which are recognized by the immune system as vulnerabilities within tumor cells. By exploiting these weak points, the company seeks to enhance clinical outcomes for cancer patients, providing a promising approach to cancer therapy.

Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, focused on the discovery and development of innovative therapies aimed at enhancing anti-tumour immune responses. Established in 2014, the company utilizes a specialized technology platform that selectively delivers small molecule drugs to tumour-associated macrophages. This targeted approach aims to activate the body’s natural immune system, empowering it to combat cancer more effectively. By focusing on the interaction between immune cells and tumours, Macrophage Pharma seeks to develop novel treatments that improve patient outcomes in cancer therapy.

Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, specializing in the development of patient-specific immunotherapies designed to combat cancer. Founded in 2016, the company focuses on personalized vaccines and T cell therapies that utilize the body's immune system to target and eliminate cancer cells. Achilles Therapeutics aims to identify and target truncal tumor neoantigens and other markers present on cancer cells, allowing for precise attacks on tumors while sparing healthy tissue. The company is currently conducting clinical trials, including the CHIRON trial for non-small-cell lung cancer and the THETIS trial for recurrent or metastatic melanoma, to evaluate the efficacy and safety of its innovative therapies.